Vir Biotechnology to present hepatitis delta trial data at EASL Congress

May 18, 2026 4:05 PM

Vir Biotechnology Inc. (NASDAQ: VIR) will present data from its Phase 2 SOLSTICE clinical trial evaluating treatments for chronic hepatitis ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found